Analysis of O-linked Glycosylation

Scientists at Genovis have discovered new O-glycan-specific enzymatic tools including: OpeRATOR™ - an O-glycan-specific endoprotease, OglyZOR™ - an O-glycosidase, SialEXO™ - a sialidase mix for removal of sialic acids. The enzymes allow detailed characterization of O-glycosylations, both in terms of site occupancy and composition determination as demonstrated below.




OpeRATOR is available for ordering. Buy online or visit 'How to order'. 

Antibody Characterization

Scientific Posters

Download posters on OpeRATOR and the enzymes for O-glycans here


OpeRATOR™ Product Page

The OpeRATOR enzyme digests O-glycosylated proteins N-terminally of the serine and threonine glycosylation sites

OpeRATOR Activity

We have discovered an O-glycan-specific endoprotease - OpeRATOR, digesting O-glycoproteins N-terminally of the serine and threonine glycosylation sites. This generates glycopeptides carrying O-glycans and enables O-glycan profiling, O-glycopeptide mapping as well as middle level analyses using mass spectrometry. Below you find a schematic overview of the OpeRATOR digestion sites (Fig. 1). O-glycans are required for OpeRATOR activity and the enzyme is not active at N-glycans. With OpeRATOR and SialEXO treatment, the O-glycosylated protein is digested into peptides carrying O-glycans. The digestion occurs N-terminally of the O-glycosylation sites. 


Figure 1. Schematic overview of the OpeRATOR activity

LC-MS Analysis of Etanercept using OpeRATOR Maps O-glycan Sites

Etanercept is an Fc-fusion protein with a highly O-glycosylated hinge region. Etanercept was incubated with OpeRATOR and the resulting glycopeptides were analyzed using LC-MS/MS. Due to the heterogeneity in the O-glycan pattern of the protein and the OpeRATOR specificity for O-glycan structures, overlapping peptides were formed that made it possible to acquire a complete map of the O-glycan sites (Fig. 2). 




Figure 2. OpeRATOR digestion of the O-glycosylated hinge region of etanercept. OpeRATOR generates overlapping peptides, making it possible to map the O-glycan sites.


O-glycan Site-specific Digestion of EPO using OpeRATOR

The specificity of OpeRATOR is here demonstrated using erythropoietin (EPO) as a substrate. EPO is a ~30 kDa glycoprotein with a single O-glycosylation site. N-glycans were removed from EPO using PNGaseF and sialic acids were removed using SialEXO. In parallel, OpeRATOR hydrolyzed the protein N-terminally of the serine O-glycan site. After reduction of disulfide bridges with DTT, the resulting two fragments were separated on a RP C4 column and intact mass was analyzed with a Bruker Impact II ESI QTOF MS (Fig. 3).



Figure 3. Specific digestion N-terminally of the O-glycosylation site. The reduced fragments were separated on a reversed phase C4 column followed by ESI-QTOF MS detection. The EPO protein carrying one core 1 O-glycan was hydrolyzed at a single specific site N-terminally of the O-glycosylated serine.



Protease Specific for O-glycans

The OpeRATOR enzyme digests O-glycosylated proteins N-terminally of the glycosylation sites.

  • Digests native O-glycosylated proteins
  • 2 h to overnight (16-18 h) reaction
  • Desialylation using SialEXO™ (included) increases performance
  • N-terminally of the O-glycosylated serine or threonine



Removal of Sialic Acids from Native Glycoproteins

SialEXO efficiently hydrolyzes all sialic acids from native glycoproteins.

  • Hydrolyzes sialic acids on N- and O-linked glycans
  • 2 h reaction
  • Requires no co-factors
  • α2-3, α2-6 and α2-8-linked sialic acids

Patent and Disclaimer

OpeRATOR™ and SialEXO™

All rights reserved. Aspects of OpeRATOR™ and SialEXO™ technologies are encompassed by pending patent applications in the name of Genovis AB.

The trademarks OpeRATOR™ and SialEXO™ are the property of Genovis AB.

For research use only. Not intended for any animal or human therapeutic or diagnostic use.

©2018 Genovis AB.